(Q38116765)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23797465%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

title

Targeted delivery of nano-therapeutics for major disorders of the central nervous system (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23797465%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

1 reference

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23797465%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

author name string

Zhiqing Pang

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23797465%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Xinguo Jiang

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23797465%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

language of work or name

1 reference

1 October 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23797465%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

published in

Pharmaceutical Research

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23797465%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

volume

30

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23797465%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23797465%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

page(s)

2485-2498

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23797465%20AND%20SRC:MED&resulttype=core&format=json

Transport of drugs across the blood-brain barrier by nanoparticles.

3 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

Delivery of therapeutic agents to the central nervous system: the problems and the possibilities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

Delivery of peptide and protein drugs over the blood-brain barrier

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

Drug targeting to the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

Perspectives on brain-targeting drug delivery systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

Nanotechnology-novel therapeutics for CNS disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

Recent advances in brain tumor-targeted nano-drug delivery systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

Drug delivery strategies for the treatment of malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

Novel drug delivery strategies in neuro-oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

Recent advances in therapy for glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

The disturbed blood-brain barrier in human glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

Function of the blood-brain barrier and restriction of drug delivery to invasive glioma cells: findings in an orthotopic rat xenograft model of glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

ABCC drug efflux pumps and organic anion uptake transporters in human gliomas and the blood-tumor barrier

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

Host microvasculature influence on tumor vascular morphology and endothelial gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

The blood-brain/tumor barriers: challenges and chances for malignant gliomas targeted drug delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

Physiologic upper limit of pore size in the blood-tumor barrier of malignant solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

Effective transvascular delivery of nanoparticles across the blood-brain tumor barrier into malignant glioma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

Expression of multidrug resistance-associated protein (MRP) in human gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

Human brain tumors: multidrug-resistance P-glycoprotein expression in tumor cells and intratumoral capillary endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

Lapatinib distribution in HER2 overexpressing experimental brain metastases of breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

Enhanced intracellular delivery and chemotherapy for glioma rats by transferrin-conjugated biodegradable polymersomes loaded with doxorubicin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

Preparation and brain delivery property of biodegradable polymersomes conjugated with OX26.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

Aclarubicin-loaded cationic albumin-conjugated pegylated nanoparticle for glioma chemotherapy in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

Cationic albumin-conjugated pegylated nanoparticles allow gene delivery into brain tumors via intravenous administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

Anti-glioma effect and safety of docetaxel-loaded nanoemulsion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

Surface expressed nucleolin is constantly induced in tumor cells to mediate calcium-dependent ligand internalization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

Targeted delivery of RGD-modified liposomes encapsulating both combretastatin A-4 and doxorubicin for tumor therapy: in vitro and in vivo studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

Targeted delivery of chlorotoxin-modified DNA-loaded nanoparticles to glioma via intravenous administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

Discovery and development of anticancer aptamers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

Aptamer-functionalized PEG-PLGA nanoparticles for enhanced anti-glioma drug delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

Whole-cell SELEX aptamer-functionalised poly(ethyleneglycol)-poly(ε-caprolactone) nanoparticles for enhanced targeted glioblastoma therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

PEG-co-PCL nanoparticles modified with MMP-2/9 activatable low molecular weight protamine for enhanced targeted glioblastoma therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

Tumor imaging by means of proteolytic activation of cell-penetrating peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

Targeted delivery of cargoes into a murine solid tumor by a cell-penetrating peptide and cleavable poly(ethylene glycol) comodified liposomal delivery system via systemic administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

Efficient delivery of payload into tumor cells in a controlled manner by TAT and thiolytic cleavable PEG co-modified liposomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

"SMART" drug delivery systems: double-targeted pH-responsive pharmaceutical nanocarriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

Esterase-catalyzed dePEGylation of pH-sensitive vesicles modified with cleavable PEG-lipid derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

TRAIL and doxorubicin combination enhances anti-glioblastoma effect based on passive tumor targeting of liposomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

Co-delivery of TRAIL gene enhances the anti-glioblastoma effect of paclitaxel in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

Ligands for mapping alphavbeta3-integrin expression in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

Targeting the brain with PEG-PLGA nanoparticles modified with phage-displayed peptides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

Precise glioma targeting of and penetration by aptamer and peptide dual-functioned nanoparticles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

Anti-tumor activity of paclitaxel through dual-targeting carrier of cyclic RGD and transferrin conjugated hyperbranched copolymer nanoparticles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

A dual-targeting nanocarrier based on poly(amidoamine) dendrimers conjugated with transferrin and tamoxifen for treating brain gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

Transferrin-modified c[RGDfK]-paclitaxel loaded hybrid micelle for sequential blood-brain barrier penetration and glioma targeting therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

Dual-targeted polyplexes: one step towards a synthetic virus for cancer gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

Dual-targeting daunorubicin liposomes improve the therapeutic efficacy of brain glioma in animals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

PEGylated Poly(amidoamine) dendrimer-based dual-targeting carrier for treating brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

Dual-targeting topotecan liposomes modified with tamoxifen and wheat germ agglutinin significantly improve drug transport across the blood-brain barrier and survival of brain tumor-bearing animals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

Dual-ligand effect of transferrin and transforming growth factor alpha on polyethyleneimine-mediated gene delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

Functional characterization of the brain-to-blood efflux clearance of human amyloid-beta peptide (1-40) across the rat blood-brain barrier.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

Transferrin/transferrin receptor-mediated drug delivery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

Identification and design of peptides as a new drug delivery system for the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

Gene delivery targeted to the brain using an Angiopep-conjugated polyethyleneglycol-modified polyamidoamine dendrimer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

Anti-glioblastoma efficacy and safety of paclitaxel-loading Angiopep-conjugated dual targeting PEG-PCL nanoparticles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

Nanotechnology for neurodegenerative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

Intravenous delivery of targeted liposomes to amyloid-β pathology in APP/PSEN1 transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

Tau suppression in a neurodegenerative mouse model improves memory function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

Anti-Abeta antibody treatment promotes the rapid recovery of amyloid-associated neuritic dystrophy in PDAPP transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

Receptor-mediated abeta amyloid antibody targeting to Alzheimer's disease mouse brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

Wheat germ agglutinin enhanced cerebral uptake of anti-Aβ antibody after intranasal administration in 5XFAD mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

Curcumin has potent anti-amyloidogenic effects for Alzheimer's beta-amyloid fibrils in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

Curcumin loaded-PLGA nanoparticles conjugated with Tet-1 peptide for potential use in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

Effect of curcumin-associated and lipid ligand-functionalized nanoliposomes on aggregation of the Alzheimer's Aβ peptide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

ApoE3 mediated poly(butyl) cyanoacrylate nanoparticles containing curcumin: study of enhanced activity of curcumin against beta amyloid induced cytotoxicity using in vitro cell culture model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

A novel peptide defined through phage display for therapeutic protein and vector neuronal targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

Nanotechnologies for Alzheimer's disease: diagnosis, therapy, and safety issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

Novel D-penicillamine carrying nanoparticles for metal chelation therapy in Alzheimer's and other CNS diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

Pharmacological and toxicological target organelles and safe use of single-walled carbon nanotubes as drug carriers in treating Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

Nanoparticulate systems for brain delivery of drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

Poly(n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

Rivastigmine-loaded PLGA and PBCA nanoparticles: preparation, optimization, characterization, in vitro and pharmacodynamic studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

[Gly(14)]-Humanin improved the learning and memory impairment induced by scopolamine in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

Self-assembled polymersomes conjugated with lactoferrin as novel drug carrier for brain delivery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

Brain delivery of NAP with PEG-PLGA nanoparticles modified with phage display peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

Ameliorative effect of NC-1900, a new AVP4-9 analog, through vasopressin V1A receptor on scopolamine-induced impairments of spatial memory in the eight-arm radial maze

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

Brain delivery of vasoactive intestinal peptide enhanced with the nanoparticles conjugated with wheat germ agglutinin following intranasal administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

Lectin-conjugated PEG-PLA nanoparticles: preparation and brain delivery after intranasal administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

Odorranalectin is a small peptide lectin with potential for drug delivery and targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

A novel small Odorranalectin-bearing cubosomes: preparation, brain delivery and pharmacodynamic study on amyloid-β₂₅₋₃₅-treated rats following intranasal administration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

Intrajejunal levodopa versus conventional therapy in Parkinson disease: motor and nonmotor effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

Stem cell therapy ameliorates bladder dysfunction in an animal model of Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

Exercise and physical therapy in early management of Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

Monoclonal antibody-glial-derived neurotrophic factor fusion protein penetrates the blood-brain barrier in the mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

The corticotrophin-releasing factor-like peptide urocortin reverses key deficits in two rodent models of Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

Lactoferrin-conjugated PEG-PLA nanoparticles with improved brain delivery: in vitro and in vivo evaluations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

Lactoferrin conjugated PEG-PLGA nanoparticles for brain delivery: preparation, characterization and efficacy in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

Intravenous nonviral gene therapy causes normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental parkinsonism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

Neurotensin polyplex as an efficient carrier for delivering the human GDNF gene into nigral dopamine neurons of hemiparkinsonian rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

NTS-Polyplex: a potential nanocarrier for neurotrophic therapy of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

The use of lactoferrin as a ligand for targeting the polyamidoamine-based gene delivery system to the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

Neuroprotection in a 6-hydroxydopamine-lesioned Parkinson model using lactoferrin-modified nanoparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

A delivery strategy for rotenone microspheres in an animal model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

Behavioral differences in a rotenone-induced hemiparkinsonian rat model developed following intranigral or median forebrain bundle infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

Gene therapy using lactoferrin-modified nanoparticles in a rotenone-induced chronic Parkinson model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

Risk factors and cerebrovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

Extended therapeutic time window after focal cerebral ischemia by non-competitive inhibition of AMPA receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

Neuroprotection with noninvasive neurotrophin delivery to the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

Conjugation of brain-derived neurotrophic factor to a blood-brain barrier drug targeting system enables neuroprotection in regional brain ischemia following intravenous injection of the neurotrophin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

Neuroprotection in experimental stroke with targeted neurotrophins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

Enhanced neuroprotective effects of basic fibroblast growth factor in regional brain ischemia after conjugation to a blood-brain barrier delivery vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

Site-specific modifications and toxicity of blood substitutes. The case of diaspirin cross-linked hemoglobin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

Pharmacokinetics of 125I-radiolabelled PEG-hemoglobin SB1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

Neuroprotective effects of the novel polyethylene glycol-hemoglobin conjugate SB1 on experimental cerebral thromboembolism in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

Nanoparticle-mediated delivery of superoxide dismutase to the brain: an effective strategy to reduce ischemia-reperfusion injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

Immunosuppression promotes endogenous neural stem and progenitor cell migration and tissue regeneration after ischemic injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

Transport of epidermal growth factor in the stroke-injured brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

Hydrogel delivery of erythropoietin to the brain for endogenous stem cell stimulation after stroke injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

VEGF-induced neuroprotection, neurogenesis, and angiogenesis after focal cerebral ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

HMGB1, a novel cytokine-like mediator linking acute neuronal death and delayed neuroinflammation in the postischemic brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

Neuroprotection by biodegradable PAMAM ester (e-PAM-R)-mediated HMGB1 siRNA delivery in primary cortical cultures and in the postischemic brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

Biochemical pathways of caspase activation during apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

Functional motor recovery from brain ischemic insult by carbon nanotube-mediated siRNA silencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

Dexamethasone-loaded peptide micelles for delivery of the heme oxygenase-1 gene to ischemic brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

Intranasally delivered bFGF enhances neurogenesis in adult rats following cerebral ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

Intranasal deferoxamine provides increased brain exposure and significant protection in rat ischemic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

Intranasal brain-derived neurotrophic factor protects brain from ischemic insult via modulating local inflammation in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

Acidic fibroblast growth factor delivered intranasally induces neurogenesis and angiogenesis in rats after ischemic stroke.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

Intranasal ginsenoside Rb1 targets the brain and ameliorates cerebral ischemia/reperfusion injury in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

Intranasal delivery of HMGB1-binding heptamer peptide confers a robust neuroprotection in the postischemic brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

Suppression of local inflammation contributes to the neuroprotective effect of ginsenoside Rb1 in rats with cerebral ischemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

Intranasal delivery of HMGB1 siRNA confers target gene knockdown and robust neuroprotection in the postischemic brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

Polymeric micelles anchored with TAT for delivery of antibiotics across the blood-brain barrier

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

Development and evaluation of rivastigmine loaded chitosan nanoparticles for brain targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

Antinociceptive properties of nasal delivery of neurotoxin-loaded nanoparticles coated with polysorbate-80.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

Preparation and therapeutic efficacy of polysorbate-80-coated amphotericin B/PLA-b-PEG nanoparticles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

From nose to brain: understanding transport capacity and transport rate of drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11095-013-1122-4

The blood-brain and blood-tumor barriers: a review of strategies for increasing drug delivery

21 January 2018

1 reference

12 December 2020

Impulse control disorders in Parkinson disease: is cognitive-behavioral therapy worth a wager?

1 reference

12 December 2020

Blood-brain barrier drug targeting enables neuroprotection in brain ischemia following delayed intravenous administration of neurotrophins

1 reference

12 December 2020

Growth factor-stimulated generation of new cortical tissue and functional recovery after stroke damage to the motor cortex of rats.

1 reference

12 December 2020

Human glioblastoma cell lines: levels of low-density lipoprotein receptor and low-density lipoprotein receptor-related protein.

1 reference

12 December 2020

Intranasal recombinant human erythropoietin protects rats against focal cerebral ischemia

1 reference

12 December 2020

Enhanced brain drug delivery: safely crossing the blood-brain barrier

1 reference

12 December 2020

Odorranalectin-conjugated nanoparticles: preparation, brain delivery and pharmacodynamic study on Parkinson's disease following intranasal administration

1 reference

12 December 2020

Gene therapy for Parkinson's disease

1 reference

12 December 2020

Co-delivery of pEGFP-hTRAIL and paclitaxel to brain glioma mediated by an angiopep-conjugated liposome

1 reference

12 December 2020

Postacute ischemia vascular endothelial growth factor transfer by transferrin-targeted liposomes attenuates ischemic brain injury after experimental stroke in rats

1 reference

12 December 2020

CNS drug design based on principles of blood-brain barrier transport

1 reference

12 December 2020

Curcumin-decorated nanoliposomes with very high affinity for amyloid-β1-42 peptide

1 reference

12 December 2020

Micelle-based brain-targeted drug delivery enabled by a nicotine acetylcholine receptor ligand

1 reference

12 December 2020

1 reference

12 December 2020

Controlled epi-cortical delivery of epidermal growth factor for the stimulation of endogenous neural stem cell proliferation in stroke-injured brain

1 reference

12 December 2020

The ability of polyethylene glycol conjugated bovine hemoglobin (PEG-Hb) to adequately deliver oxygen in both exchange transfusion and top-loaded rat models

1 reference

12 December 2020

Primary brain tumours in adults

1 reference

12 December 2020

Neuroimaging of cerebrovascular disease in the aging brain.

1 reference

12 December 2020